The US Food and Drug Administration (FDA) has recently rolled back certain regulatory requirements for lab-developed tests (LDTs), a decision that has sparked renewed discussions about clinical ivermectin studies 2025 usa , patient safety, regulatory accountability, and drug access. While LDTs ​​were previously held to strict FDA oversight standards, the rollback now allows...

The U.S. healthcare landscape is in a transformative phase. The rapid surge of GLP-1 obesity drugs and persistent discussions around ivermectin and GLP-1 healthcare discussions represent a clash of priorities in modern medicine. At the same time, the telehealth boom is changing how Americans access care, raising complex questions about health privacy,...